...also said the decoys lack the bleeding risks associated with approved antiplatelet therapies such as abciximab...

...CD41/CD61) inhibitors Integrilin and Aggrastat tirofiban and Johnson & Johnson markets the CD41/CD61 mAb ReoPro abciximab...

...Indeed, there are three inhibitors on the market: Johnson & Johnson markets the mAb ReoPro abciximab...

...infarction (STEMI) undergoing percutaneous coronary intervention (PCI) showed that a 0.25 mg/kg bolus of intracoronary ReoPro...
...15.1% vs. 17.9%, p=0.03) and median absolute infarct mass vs. patients who did not receive ReoPro...
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ReoPro abciximab...

...trial in 1,721 patients with acute with non-ST-segment-elevation myocardial infarction (NSTEMI) undergoing PCI showing that ReoPro...
...MI, urgent TVR and major bleeding at 30 days vs. bivalirudin (10.9% vs. 11%, p=0.94). ReoPro...
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ReoPro abciximab...

...all bleeding events according to TIMI criteria within 30 days of treatment compared to ReoPro abciximab...
...in bleeding events with ALX-0081 vs. ReoPro. Additionally, 3 and 2 patients receiving ALX-0081 and ReoPro...
...end of 2013. ALX-0081 has Orphan Drug designation in the U.S. and EU for TTP. ReoPro...

...a composite rate of all bleeding events within 30 days of treatment compared to ReoPro abciximab...
...expected by year end 2013. Ablynx was off EUR 0.02 to EUR 2.69 on Thursday. ReoPro...

...from Medicure Inc. (TSX:MPH, Winnipeg, Manitoba), Iroko Pharmaceuticals LLC (Philadelphia, Pa.) and Merck; and ReoPro abciximab...

...from Medicure Inc. (TSX:MPH, Winnipeg, Manitoba), Iroko Pharmaceuticals LLC (Philadelphia, Pa.) and Merck; and ReoPro abciximab...
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ReoPro abciximab...

...Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.); Aggrastat tirofiban from Medicure, Iroko and Merck; and ReoPro abciximab...